| 查看: 558 | 回复: 3 | |||
[交流]
西替利嗪在儿童用药的主要风险是什么?
|
|
西替利嗪用于儿童,不同资料说法不一:包括“不推荐用于6岁以下儿童”,“不推荐用于12岁以下儿童”,“2岁以下儿童禁用”,“可用于儿童及妊娠或哺乳的妇女”不一而足。 目前权威的说法是? 西替利嗪在儿童用药的主要风险是什么? 希望有最新资料的站友给予解释 |
» 猜你喜欢
酰胺脱乙酰基
已经有9人回复
有时候真觉得大城市人没有县城人甚至个体户幸福
已经有3人回复
CSC & MSCA 博洛尼亚大学能源材料课题组博士/博士后招生|MSCA经费充足、排名优
已经有5人回复
有70后还继续奋斗在职场上的吗?
已经有6人回复
博士延得我,科研能力直往上蹿
已经有7人回复
退学或坚持读
已经有27人回复
面上基金申报没有其他的参与者成吗
已经有5人回复
遇见不省心的家人很难过
已经有22人回复
» 本主题相关价值贴推荐,对您同样有帮助:
转:用创新承载梦想--扬子江药业致力新品名品开发研制巡礼
已经有15人回复
【转帖】强生制药双阴影:召回局未了,质量门添忧
已经有0人回复
» 抢金币啦!回帖就可以得到:
南方医科大学中药学院 申请考核博士一名 (天然药化方向,天然产物分离经验优先)
+1/270
西南科技大学曹克课题组招收2026级申请考核制有机化学博士研究生
+1/188
Postdoctoral Research Fellow Position in Causal Inference Weill CorneIl Medicine
+1/92
供应爱德华RV 3、RV 12,阿特拉斯及莱宝真空品牌油泵及分子泵等真空产品15216851283
+1/87
博后平台选择
+1/62
香港科技大学计算物理及流体力学课题组招收全奖博士后及博士生(2026年9月入学)
+1/43
山东科技大学招聘化学化工博士博士后
+1/26
江西理工大学 稀土学院 稀土功能材料方向 招收2026届博士研究生、硕士研究生
+1/26
苏州大学招收申请考核制博士生、博士后(2026)
+1/21
澳科大药诚招2026年秋季药剂学/生物材料硕士研究生
+1/16
江汉大学轩亮教授课题组招博士研究生/博士后
+1/10
国家级海外高层次人才计划申报-博士后专项计划
+1/6
澳科大招收2026年秋季入学生物材料方向全奖博士研究生(3月5日截止)
+1/5
邵阳学院食品与化学工程学院硕士调剂
+1/3
武汉理工大学数学与统计学院张秀军教授课题组招收2026级秋季博士研究生
+1/3
山东第一医科大学第一附属医院招聘事业编制科研岗
+1/2
哈工大(深圳)罗文坚教授课题组诚招2026级博士生
+1/2
双一流联合团队招聘团队青年人才与博后
+1/1
上海理工大学“新能源材料”专业-赵斌教授招收申请考核制博士生【能源催化方向】
+1/1
岭南大学(香港)诚招固态电池、热管理材料方向优秀博士生
+1/1
2楼2011-07-13 14:49:57
3楼2011-07-13 21:28:14
★
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
qinhy(金币+1): 谢谢回帖交流~ 2011-07-14 17:55:39
|
以下是国外网站的资料,显示对6个月以上儿童进行过安全性评价,应该可以使用。 国外上市的有片剂、糖浆剂和咀嚼片。 ZYRTEC (cetirizine) can be taken without regard to food consumption. ZYRTEC (cetirizine) is available as 5 mg and 10 mg tablets, 1 mg/mL syrup, and 5 mg and 10 mg chewable tablets which can be taken with or without water. Adults and Children 12 Years and Older: The recommended initial dose of ZYRTEC (cetirizine) is 5 mg or 10 mg per day in adults and children 12 years and older, depending on symptom severity. Most patients in clinical trials started at 10 mg. ZYRTEC (cetirizine) is given as a single daily dose. The time of administration may be varied to suit individual patient needs. Children 6 to 11 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 6 to 11 years is 5 mg or 10 mg once daily depending on symptom severity. The time of administration may be varied to suit individual patient needs. Children 2 to 5 Years: The recommended initial dose of ZYRTEC (cetirizine) in children aged 2 to 5 years is 2.5 mg (? teaspoon) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoon syrup once a day or one ? teaspoon syrup given every 12 hours, or one 5 mg chewable tablet once a day. Children 6 months to <2 years: The recommended dose of ZYRTEC (cetirizine) syrup in children 6 months to 23 months of age is 2.5 mg (? teaspoon) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ? teaspoon (2.5 mg) every 12 hours. Syrup is recommended for children under the age of 2 years. Pediatric Use: The safety of ZYRTEC (cetirizine) has been demonstrated in pediatric patients aged 6 months to 11 years. The safety of ZYRTEC (cetirizine) , at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials lasting up to four weeks and in 254 patients in a non-placebo-controlled 12-week trial. The safety of cetirizine has been demonstrated in 168 patients aged 2 to 5 years in placebo-controlled trials of up to 4 weeks duration. On a mg/kg basis, most of the 168 patients received between 0.2 and 0.4 mg/kg of cetirizine HCl. The safety of cetirizine in 399 patients aged 12 to 24 months has been demonstrated in a placebo-controlled 18-month trial, in which the average dose was 0.25 mg/kg bid, corresponding to a range of 4 to 11 mg/day. The safety of ZYRTEC (cetirizine) syrup has been demonstrated in 42 patients aged 6 to 11 months in a placebo-controlled 7-day trial. The prescribed dose was 0.25 mg/kg bid, which corresponded to a mean of 4.5 mg/day, with a range of 3.4 to 6.2 mg/day. The effectiveness of ZYRTEC (cetirizine) for the treatment of allergic rhinitis and chronic idiopathic urticaria in pediatric patients aged 6 months to 11 years is based on an extrapolation of the demonstrated efficacy of ZYRTEC (cetirizine) in adults with these conditions and the likelihood that the disease course, pathophysiology and the drug's effect are substantially similar between these two populations. Efficacy is extrapolated down to 6 months of age for perennial allergic rhinitis and down to 2 years of age for seasonal allergic rhinitis because these diseases are thought to occur down to these ages in children. The recommended doses for the pediatric population are based on cross-study comparisons of the pharmacokinetics and pharmacodynamics of cetirizine in adult and pediatric subjects and on the safety profile of cetirizine in both adult and pediatric patients at doses equal to or higher than the recommended doses. The cetirizine AUC and Cmax in pediatric subjects aged 6 to 23 months who received a mean of 2.3 mg in a single dose, and in subjects aged 2 to 5 years who received a single dose of 5 mg of cetirizine syrup and in pediatric subjects aged 6 to 11 years who received a single dose of 10 mg of cetirizine syrup were estimated to be intermediate between that observed in adults who received a single dose of 10 mg of cetirizine tablets and those who received a single dose of 20 mg of cetirizine tablets. The safety and effectiveness of cetirizine in pediatric patients under the age of 6 months have not been established. Last reviewed on RxList: 5/17/2007 This monograph has been modified to include the generic and brand name in many instances. 别人的回复,贴到这,与同道共享 |
4楼2011-07-14 10:35:31













回复此楼